NONINVASIVE PERSONALIZATION OF LUNG CANCER THERAPY USING A NEW, CLINICAL-GRADE ASSAY FOR PLASMA-BASED MEASUREMENT AND MONITORING OF TUMOR GENOTYPE

Dana-Farber Cancer Institute, Inc.

Investigators